Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate

Vaccine

Volumn 28, Issue 14, 2010, Pages 2580-2592

  Singh, Balwan ^a   Cabrera Mora, Monica ^a   Jiang, Jianlin ^a   Galinski, Mary ^a,b   Moreno, Alberto ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chimeric vaccine; Malaria; T cell epitopes

Indexed keywords

ANTIPARASITIC AGENT; CHIMERIC PROTEIN; EPITOPE; MALARIA VACCINE; PLASMODIUM YOELII MEROZOITE SURFACE PROTEIN 1; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; FEMALE; GENETIC LINKAGE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MALARIA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM MALARIAE; PLASMODIUM YOELII; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANEMIA; ANIMALS; ANTIBODIES, PROTOZOAN; BASE SEQUENCE; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; MALARIA; MALARIA VACCINES; MALE; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PARASITEMIA; PLASMODIUM YOELII; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 77649338002     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.019     Document Type: Article

References (79)

1. WHO. World malaria Report 2008 (2008), WHO Press, Geneva
2. Langhorne J., Ndungu F.M., Sponaas A.M., and Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 9 7 (2008) 725-732
3. Conway D.J., Cavanagh D.R., Tanabe K., Roper C., Mikes Z.S., Sakihama N., et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 6 6 (2000) 689-692
4. Bejon P., Lusingu J., Olotu A., Leach A., Lievens M., Vekemans J., et al. Efficacy of RTS, S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med 359 24 (2008) 2521-2532
5. Kester K.E., Cummings J.F., Ockenhouse C.F., Nielsen R., Hall B.T., Gordon D.M., et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26 18 (2008) 2191-2202
6. Abdulla S., Oberholzer R., Juma O., Kubhoja S., Machera F., Membi C., et al. Safety and immunogenicity of RTS, S/AS02D malaria vaccine in infants. N Engl J Med 359 24 (2008) 2533-2544
7. Caro-Aguilar I., Lapp S., Pohl J., Galinski M.R., and Moreno A. Chimeric epitopes delivered by polymeric synthetic linear peptides induce protective immunity to malaria. Microbes Infect 7 13 (2005) 1324-1337
8. Caro-Aguilar I., Rodriguez A., Calvo-Calle J.M., Guzman F., De la Vega P., Patarroyo M.E., et al. Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens. Infect Immun 70 7 (2002) 3479-3492
9. Silva-Flannery L.M., Cabrera-Mora M., Jiang J., and Moreno A. Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine. Microbes Infect 11 1 (2009) 83-91
10. Pizarro J.C., Chitarra V., Calvet C., Verger D., and Bentley G.A. Crystallization and preliminary structural analysis of an antibody complex formed with PfMSP1-19, a malaria vaccine candidate. Acta Crystallogr 58 Pt 7 (2002) 1246-1248
11. Pizarro J.C., Chitarra V., Verger D., Holm I., Petres S., Dartevelle S., et al. Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. J Mol Biol 328 5 (2003) 1091-1103
12. Pizarro J.C., Vulliez-Le Normand B., Chesne-Seck M.L., Collins C.R., Withers-Martinez C., Hackett F., et al. Crystal structure of the malaria vaccine candidate apical membrane antigen 1. Science 308 5720 (2005) 408-411
13. Coley A.M., Gupta A., Murphy V.J., Bai T., Kim H., Anders R.F., et al. Structure of the malaria antigen AMA1 in complex with a growth-inhibitory antibody. PLoS Pathog 3 9 (2007) 1308-1319
14. Nair M., Hinds M.G., Coley A.M., Hodder A.N., Foley M., Anders R.F., et al. Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1). J Mol Biol 322 4 (2002) 741-753
15. Bentley G.A. Functional and immunological insights from the three-dimensional structures of Plasmodium surface proteins. Curr Opin Microbiol 9 4 (2006) 395-400
16. Holder A.A., and Freeman R.R. Immunization against blood stage rodent malaria using prurified parasite antigens. Nature 294 (1981) 361-364
17. del Portillo H.A., Gysin J., Mattei D.M., Khouri E., Udagama P.V., Mendis K.N., et al. Plasmodium vivax: cloning and expression of a major blood-stage surface antigen. Exp Parasitol 67 2 (1988) 346-353
18. Holder A.A., and Freeman R.R. Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med 156 5 (1982) 1528-1538
19. Holder A.A., Lockyer M.J., Odink K.G., Sandhu J.S., Riveros-Moreno V., Nicholls S.C., et al. Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature 317 6034 (1985) 270-273
20. Blackman M.J., Heidrich H.G., Donachie S., McBride J.S., and Holder A.A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172 1 (1990) 379-382
21. Blackman M.J., and Holder A.A. Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol 50 2 (1992) 307-315
22. Blackman M.J., Ling I.T., Nicholls S.C., and Holder A.A. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 49 (1991) 29-34
23. Blackman M.J., Scott-Finnigan T.J., Shai S., and Holder A.A. Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med 180 (1994) 389-393
24. Daly T.M., and Long C.A. A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun 61 6 (1993) 2462-2467
25. Rotman H.L., Daly T.M., and Long C.A. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge. Exp Parasitol 91 1 (1999) 78-85
26. Daly T.M., and Long C.A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155 1 (1995) 236-243
27. Kang Y., Calvo P.A., Daly T.M., and Long C.A. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J Immunol 161 8 (1998) 4211-4219
28. Ling I.T., Ogun S.A., and Holder A.A. Immunization against malaria with a recombinant protein. Parasite Immunol 16 2 (1994) 63-67
29. Tian J.H., Miller L.H., Kaslow D.C., Ahlers J., Good M.F., Alling D.W., et al. Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J Immunol 157 3 (1996) 1176-1183
30. Hirunpetcharat C., Tian J.H., Kaslow D.C., van Rooijen N., Kumar S., Berzofsky J.A., et al. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4 + T cells. J Immunol 159 7 (1997) 3400-3411
31. de Koning-Ward T.F., O'Donnell R.A., Drew D.R., Thomson R., Speed T.P., and Crabb B.S. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 198 6 (2003) 869-875
32. Ahlborg N., Ling I.T., Howard W., Holder A.A., and Riley E.M. Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region. Infect Immun 70 2 (2002) 820-825
33. Udhayakumar V., Anyona D., Kariuki S., Shi Y., Bloland P., Branch O., et al. Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol 154 11 (1995) 6022-6030
34. Lee E.A., Flanagan K.L., Odhiambo K., Reece W.H., Potter C., Bailey R., et al. Identification of frequently recognized dimorphic T-cell epitopes in Plasmodium falciparum merozoite surface protein-1 in West and East Africans: lack of correlation of immune recognition and allelic prevalence. Am J Trop Med Hyg 64 3 (2001) 194-203
35. Quin S.J., Seixas E.M., Cross C.A., Berg M., Lindo V., Stockinger B., et al. Low CD4(+) T cell responses to the C-terminal region of the malaria merozoite surface protein-1 may be attributed to processing within distinct MHC class II pathways. Eur J Immunol 31 1 (2001) 72-81
36. Morgan W.D., Birdsall B., Frenkiel T.A., Gradwell M.G., Burghaus P.A., Syed S.E., et al. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol 289 1 (1999) 113-122
37. Chitarra V., Holm I., Bentley G.A., Petres S., and Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. Mol Cell 3 4 (1999) 457-464
38. Egan A., Waterfall M., Pinder M., Holder A., and Riley E. Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T- cell recognition of polypeptides with numerous disulfide bonds. Infect Immun 65 8 (1997) 3024-3031
39. Hensmann M., Li C., Moss C., Lindo V., Greer F., Watts C., et al. Disulfide bonds in merozoite surface protein 1 of the malaria parasite impede efficient antigen processing and affect the in vivo antibody response. Eur J Immunol 34 3 (2004) 639-648
40. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A., et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1 3 (1995) 325-332
41. Kumar S., Collins W., Egan A., Yadava A., Garraud O., Blackman M.J., et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 68 4 (2000) 2215-2223
42. Rosa D.S., Iwai L.K., Tzelepis F., Bargieri D.Y., Medeiros M.A., Soares I.S., et al. Immunogenicity of a recombinant protein containing the Plasmodium vivax vaccine candidate MSP1(19) and two human CD4 + T-cell epitopes administered to non-human primates (Callithrix jacchus jacchus). Microbes Infect 8 8 (2006) 2130-2137
43. Rosa D.S., Tzelepis F., Cunha M.G., Soares I.S., and Rodrigues M.M. The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate. Immunol Lett 92 3 (2004) 259-268
44. Singh H., and Raghava G.P. ProPred: prediction of HLA-DR binding sites. Bioinformatics 17 12 (2001) 1236-1237
45. Mustafa A.S., Lundin K.E., Meloen R.H., Shinnick T.M., and Oftung F. Identification of promiscuous epitopes from the mycobacterial 65-kilodalton heat shock protein recognized by human CD4(+) T cells of the Mycobacterium leprae memory repertoire. Infect Immun 67 11 (1999) 5683-5689
46. Rammensee H.-G., Bachmann J., Emmerich N.P.N., Bachor O.A., and Stevanovis S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50 (1999) 213-219
47. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., and Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 19 32 (2001) 4652-4660
48. Matthews J.N., Altman D.G., Campbell M.J., and Royston P. Analysis of serial measurements in medical research. BMJ 300 6719 (1990) 230-235
49. Duh M.S., Lefebvre P., Fastenau J., Piech C.T., and Waltzman R.J. Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve. Oncologist 10 6 (2005) 438-448
50. Kaslow D.C., Hui G., and Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol 63 2 (1994) 283-289
51. Renia L., Ling I.T., Marussig M., Miltgen F., Holder A.A., and Mazier D. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun 65 11 (1997) 4419-4423
52. Vuong P.N., Richard F., Snounou G., Coquelin F., Renia L., Gonnet F., et al. Development of irreversible lesions in the brain, heart and kidney following acute and chronic murine malaria infection. Parasitology 119 Pt 6 (1999) 543-553
53. Singh S.K., Hora R., Belrhali H., Chitnis C.E., and Sharma A. Structural basis for Duffy recognition by the malaria parasite Duffy-binding-like domain. Nature 439 7077 (2006) 741-744
54. Tolia N.H., Enemark E.J., Sim B.K., and Joshua-Tor L. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum. Cell 122 2 (2005) 183-193
55. Dahlback M., Rask T.S., Andersen P.H., Nielsen M.A., Ndam N.T., Resende M., et al. Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration. PLoS Pathog 2 11 (2006) e124
56. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., et al. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun 69 3 (2001) 1536-1546
57. Ling I.T., Ogun S.A., Momin P., Richards R.L., Garcon N., Cohen J., et al. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 15 14 (1997) 1562-1567
58. Majarian W.R., Daly T.M., Weidanz W.P., and Long C.A. Passive immunization against murine malaria with an IgG3 monoclonal antibody. J Immunol 132 6 (1984) 3131-3137
59. Guevara Patino J.A., Holder A.A., McBride J.S., and Blackman M.J. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med 186 10 (1997) 1689-1699
60. Ahlborg N., Ling I.T., Holder A.A., and Riley E.M. Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19). Infect Immun 68 4 (2000) 2102-2109
61. Ogun S.A., Dumon-Seignovert L., Marchand J.B., Holder A.A., and Hill F. The oligomerization domain of C4-binding protein (C4 bp) acts as an adjuvant, and the fusion protein comprised of the 19-kilodalton merozoite surface protein 1 fused with the murine C4 bp domain protects mice against malaria. Infect Immun 76 8 (2008) 3817-3823
62. de Oliveira C.I., Wunderlich G., Levitus G., Soares I.S., Rodrigues M.M., Tsuji M., et al. Antigenic properties of the merozoite surface protein 1 gene of Plasmodium vivax. Vaccine 17 23/24 (1999) 2959-2968
63. Wunderlich G., Moura I.C., and del Portillo H.A. Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection. Infect Immun 68 10 (2000) 5839-5845
64. Yang C., Collins W.E., Sullivan J.S., Kaslow D.C., Xiao L., and Lal A.A. Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect Immun 67 1 (1999) 342-349
65. Reed Z.H., Kieny M.P., Engers H., Friede M., Chang S., Longacre S., et al. Comparison of immunogenicity of five MSP1-based malaria vaccine candidate antigens in rabbits. Vaccine 27 10 (2009) 1651-1660
66. Jeamwattanalert P., Mahakunkijcharoen Y., Kittigul L., Mahannop P., Pichyangkul S., and Hirunpetcharat C. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clin Vaccine Immunol 14 4 (2007) 342-347
67. Hirunpetcharat C., Wipasa J., Sakkhachornphop S., Nitkumhan T., Zheng Y.Z., Pichyangkul S., et al. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. Vaccine 21 21/22 (2003) 2923-2932
68. Kumar S., Jones T.R., Oakley M.S., Zheng H., Kuppusamy S.P., Taye A., et al. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine. Infect Immun 72 2 (2004) 949-957
69. Shi Q., Lynch M.M., Romero M., and Burns Jr. J.M. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect Immun 75 3 (2007) 1349-1358
70. Pattaradilokrat S., Cheesman S.J., and Carter R. Congenicity and genetic polymorphism in cloned lines derived from a single isolate of a rodent malaria parasite. Mol Biochem Parasitol 157 2 (2008) 244-247
71. Daly T.M., Burns Jr. J.M., and Long C.A. Comparison of the carboxy-terminal, cysteine-rich domain of the merozoite surface protein-1 from several strains of Plasmodium yoelii. Mol Biochem Parasitol 52 2 (1992) 279-282
72. Benjamin P.A., Ling I.T., Clottey G., Valero L.M., Ogun S.A., Fleck S.L., et al. Antigenic and sequence diversity at the C-terminus of the merozoite surface protein-1 from rodent malaria isolates, and the binding of protective monoclonal antibodies. Mol Biochem Parasitol 104 2 (1999) 147-156
73. Jongwutiwes S., Tanabe K., and Kanbara H. Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol 59 1 (1993) 95-100
74. Miller L.H., Roberts T., Shahabuddin M., and McCutchan T.F. Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 59 1 (1993) 1-14
75. Lyon J.A., Angov E., Fay M.P., Sullivan J.S., Girourd A.S., Robinson S.J., et al. Protection induced by Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and correlates with antibody responses. PLoS ONE 3 7 (2008) e2830
76. Manca F., De Berardinis P., Fenoglio D., Ombra M.N., Pira L.P., Saverino S., et al. Antigenicity of HIV-derived T helper determinants in the context of carrier recombinant proteins: effect on T helper cell repertoire selection. Eur J Immunol 26 10 (1996) 2461-2469
77. Fazilleau N., Eisenbraun M.D., Malherbe L., Ebright J.N., Pogue-Caley R.R., McHeyzer-Williams L.J., et al. Lymphoid reservoirs of antigen-specific memory T helper cells. Nat Immunol 8 7 (2007) 753-761
78. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 7 (2007) 843-850
79. Yoshida N., Nussenzweig R.S., Potocnjak P., Nussenzweig V., and Aikawa M. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 207 4426 (1980) 71-73